Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Down 14.5%, Is Pfizer Stock a Screaming Buy?

TheMotleyFool

0 0

As the major U.S. stock indices fell into bear territory in 2022, big pharma stocks quickly became an oasis for nervous investors -- in many cases thanks to their largely recession-proof business models, reliable cash flows, and dependable quarterly dividends.

AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), and Merck (NYSE: MRK) all trounced the broader markets last year: